Connection

Co-Authors

This is a "connection" page, showing publications co-authored by GREGORY A LIZEE and WILLEM OVERWIJK.
Connection Strength

1.742
  1. Harnessing the power of the immune system to target cancer. Annu Rev Med. 2013; 64:71-90.
    View in: PubMed
    Score: 0.432
  2. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 01; 19(5):1225-31.
    View in: PubMed
    Score: 0.110
  3. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15; 19(2):393-403.
    View in: PubMed
    Score: 0.109
  4. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. 2012 Nov 29; 120(23):4533-43.
    View in: PubMed
    Score: 0.107
  5. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-? inducible chemokines. Cancer Res. 2012 Oct 15; 72(20):5209-18.
    View in: PubMed
    Score: 0.107
  6. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. J Immunother. 2012 Apr; 35(3):276-82.
    View in: PubMed
    Score: 0.104
  7. Natural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts anti-tumor immunity. PLoS One. 2011; 6(8):e22939.
    View in: PubMed
    Score: 0.099
  8. Antitumor activity mediated by CpG: the route of administration is critical. J Immunother. 2011 Apr; 34(3):279-88.
    View in: PubMed
    Score: 0.097
  9. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res. 2010 Nov 15; 16(22):5458-68.
    View in: PubMed
    Score: 0.094
  10. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008 Mar; 118(3):1165-75.
    View in: PubMed
    Score: 0.078
  11. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int Immunol. 2007 Oct; 19(10):1213-21.
    View in: PubMed
    Score: 0.076
  12. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res. 2006 Aug 15; 12(16):4794-803.
    View in: PubMed
    Score: 0.070
  13. Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2359s-2365s.
    View in: PubMed
    Score: 0.069
  14. Correction: IL-1a Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. J Immunol. 2024 Feb 01; 212(3):500.
    View in: PubMed
    Score: 0.059
  15. IL-1a Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. J Immunol. 2021 04 15; 206(8):1966-1975.
    View in: PubMed
    Score: 0.048
  16. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017 Nov 14; 8(57):96496-96505.
    View in: PubMed
    Score: 0.038
  17. Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination. J Immunother. 2013 May; 36(4):276-86.
    View in: PubMed
    Score: 0.028
  18. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine. 2007 Nov 14; 25(46):7955-61.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.